The psychedelic pioneers at Mydecine Innovations Group have just signed a 5-year partnership with the prestigious research institute at Johns Hopkins University. The goal of the collaboration will be to advance their psychedelic-based research into cigarette cessation in tobacco smokers. The study will be led by Dr. Matthew Johnson, a prominent researcher in the field who was president of the Psychopharmacology and Substance Abuse Division of the American Psychological Association.
In a recent press release, Mydecine CEO Josh Bartch said-
“We are excited to expand on the current work we are conducting with Dr. Matt Johnson and his team at JHU in regards to smoking cessation to include numerous other projects over the next five years. The researchers at JHU have proven their incredible depth of knowledge in the field.”
The agreement will allow Hopkins and Mydecine to further collaborate on research into novel psychedelic therapies to treat conditions such as addiction disorders. Mydecine’s Chief Scientific Officer and Co-Founder, Rob Roscow, also stated in the aforementioned release that this new partnership demonstrates their commitment to advancing psychedelic medicine by exploring multiple molecules and medicines for a variety of indications.
Mydecine’s Chief Medical Officer, Dr.Rakesh Jetly, insightfully mentioned how despite much of the recent attention being given to opiate addiction, the enormous burden that nicotine dependence has on our society is often forgotten about. In Mydecine’s press release, Dr. Jetly points out that-
“According to the CDC, cigarette smoking is the leading cause of preventable disease and death in the United States, killing more than 480,000 Americans each year. Despite all the public education and dire warnings, cigarette smoking remains one of the most difficult addictions to treat and contributes to more deaths than all the other substances combined, making research like this vital.”
The phase 2/3 trial will be utilizing MYCO-001, which is pure psilocybin derived from natural fungal sources and is expected to begin in just five months. Dr. Jetly is also the principal investigator conducting the very first clinical trials investigating the use of psilocybin for PTSD.
In this informative video, The Psychedelic Investor explains how MYCO-001 has the potential to bring in hundreds of millions of dollars for Mydecine.
Mydecine expects the global market for smoking cessation to total around 64 billion dollars, despite the fact the market cap is only around 64 million dollars right now. With this Johns Hopkins partnership and their collaboration with Dr. Matthew Johnson, Mydecine may indeed become a leader in what is being dubbed as the modern “shroom boom”.
As the researchers at Mydecine hope to reproduce the historic smoking cessation trials initially performed at Johns Hopkins, they are positioning themselves to be leaders in the therapeutic mushroom market. As they join forces to run phase 2 and 3 clinical trials in hopes of treating smoking addiction with psilocybin, it will certainly be interesting to observe their progress and follow all their latest developments.